Bayrab, Hyperrab Purple Book BLA 101144

BLA number
101144
Proprietary names
Bayrab, Hyperrab, Bayrab,Hyperrab
Proper names
Rabies Immune Globulin (Human)
Applicant
Grifols Therapeutics LLC
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Bayrab, HyperrabRabies Immune Globulin (Human)351(a)300IU/MLInjectionIntramuscularSingle-Dose VialRxLicensed1974-06-12
002Bayrab, HyperrabRabies Immune Globulin (Human)351(a)1500IU/5 MLInjectionIntramuscularSingle-Dose VialRxLicensed1974-06-12
003Bayrab,HyperrabRabies Immune Globulin (Human)351(a)900 IU/ 3MLInjectionIntramuscularSingle-Dose VialRxLicensed2019-11-06

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-08-01N, U003Bayrab,Hyperrab351(a)RxGrifols Therapeutics LLC
2021-05-01U001Bayrab, Hyperrab351(a)RxGrifols Therapeutics LLC
2021-05-01U002Bayrab, Hyperrab351(a)RxGrifols Therapeutics LLC
2020-08-01R001Bayrab, Hyperrab351(a)RxGrifols Therapeutics LLC
2020-08-01R002Bayrab, Hyperrab351(a)RxGrifols Therapeutics LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2021-08-01003Bayrab,Hyperrab351(a)RxLicensed2019-11-06
2020-08-01001Bayrab, Hyperrab351(a)RxLicensed1974-06-12
2020-08-01002Bayrab, Hyperrab351(a)RxLicensed1974-06-12